TheraCryf Plc
TCF · AIM · Health Care · mcap £4.0m · 0.2p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 09 Oct 26 | Change of Nominated Adviser
TheraCryf plc, the biotech company developing new medicines for addiction and other neuropsychiatric disorders, announces that it has appointed Strand Hanson Limited as its Financial and Nominated Adviser with immediate |
−5.6% | |
| 02 Oct 26 | Australian partner to progress Ox-1 Phase 1 trial
Australian partner appointed to progress Ox-1 towards Phase 1 trial |
+0.0% | |
| 30 Sep 26 | Routine | Posting of Annual Report and Notice of AGM | |
| 28 Sep 26 | Results | Final Results
Final Results for the year ended 31 March 2026 |
+0.0% |
| 14 Sep 26 | Routine | Notice of Results and Investor Presentation | |
| 11 Sep 26 | Holding | Holding(s) in Company | |
| 10 Sep 26 | Holding | Holding(s) in Company | |
| 07 Sep 26 | Routine | Result of General Meeting | |
| 20 Aug 26 | Fundraise | Proposed Placing & Subscription to raise £1.05m
Proposed Placing and Subscription to raise £1.05 million |
+0.0% |
| 24 Jun 26 | Holding | Holding(s) in Company | |
| 26 May 26 | Holding | Holding(s) in Company | |
| 15 May 26 | Holding | Holding(s) in Company | |
| 15 May 26 | Holding | Holding(s) in Company | |
| 14 May 26 | Positive Ox-1 tox data in addiction programme
Positive top line data from first toxicology species in lead Ox-1 addiction programme |
+11.4% | |
| 21 Apr 26 | Investor Webinar
TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that Dr Huw Jones, Chief Executive Officer and Dr Helen Kuhlman, Chief Operating |
+0.0% | |
| 20 Apr 26 | Successful GMP Manufacture Advances Ox-1 to Clinic
Lead Asset Ox-1 Advances Towards Clinic With Successful GMP Manufacture For Human Use |
+0.0% | |
| 16 Apr 26 | New Manufacturing Process Patent for Ox-1
New Manufacturing Process Patent Extends Exclusivity for Lead Asset Ox-1 |
+6.7% | |
| 14 Apr 26 | Non-Binding Proposal to Acquire TheraCryf’s Assets
Non-Binding Indicative Proposal to Acquire TheraCryf's Lead Neuropsychiatry Assets Received |
+15.4% | |
| 23 Mar 26 | Ox-1 Programme Advances to Final Toxicology Study
Lead Ox-1 Programme Advances to Final Toxicology Studies Before Human Phase 1 Clinical Study |
+0.0% | |
| 26 Jan 26 | Ox-1 Addiction Programme Update
Best-in-class Ox-1 asset continues to be de-risked ahead of clinical readiness |
+0.0% | |
| 05 Jan 26 | Key Ox-1 milestone & notice of investor webinar
Ox-1 addiction programme advances closer to clinical readiness on achievement of key milestone |
+0.0% | |
| 18 Dec 25 | Potential of Preclinical Program in Mental Fatigue
· Chronic fatigue treatment market worth US$1.2 billion in 2024, rising to c.US$2.3bn by 20331 |
−4.8% | |
| 03 Dec 25 | Results | Half-year Results
Class-leading addiction programme on target to be clinic ready in 2026 |
+11.6% |
| 26 Nov 25 | Marking Addiction Awareness Week
Alderley Park, 26 November 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, is supporting Addiction Awareness Week. |
+0.0% | |
| 24 Nov 25 | Routine | Notice of Results | |
| 03 Nov 25 | Ox-1 Programme Achieves Manufacturing Milestone
Scale up of drug quantity achieved ahead of schedule |
+0.0% | |
| 16 Oct 25 | Holding | Holding(s) in Company | |
| 16 Oct 25 | Director dealing | Director/PDMR Shareholding | |
| 10 Oct 25 | World Mental Health Day & Q4 Conference Schedule
Marking World Mental Health Day and Q4 Conference Schedule Update |
+0.0% |
Company filings. Not investment advice.